Abbott is a global healthcare company founded in 1888 with headquarters in Chicago. It has expanded to over 150 countries with 74,000 employees. Abbott operates in pharmaceuticals, nutrition, diagnostics, and diabetes care. While it has a strong brand image and product quality, Abbott faces weaknesses such as slow production and centralized decision making. Opportunities include growing disease burdens and physician numbers. Threats are high inflation, political instability, and competitors. The analysis recommends Abbott focus on growth areas like heart medicines through advertising to address weaknesses and leverage strengths and opportunities.

1. Prepared by:
Syeda Zeerak (BM-35240)
Yusra Siddiqui (BME-1909)
Anum Rasheed Khan (BM-26037)
Rida Faheem (BM-26035)

2. CEO Dr. Wallace Abbott
Founded 1888
Head Quarter Chicago
Global Expansion 150 countries
Employees 74000
Slogan A promise for life

3.  1888: Dr. Wallace Abbott begins
manufacturing alkaloid pills
 1894: Abbott Alkaloidal Company
 1907: Expansion in London
 1916: First antiseptic medicine,
Chlorazene
 1922: Development of anesthesia, Butyn
 1929: Listed on Chicago stock exchange
 1942: Developed antibiotic, Penicillin
 1959: Adopt logo

4.  1964: Acquires M & R Dietitic lab.
 1972: ABA-100 blood chemistry analyzer
 1985: Diagnostic test for AIDS
 1998: Introduction of Glucerna
 2002: FDA approves Humira.
 2010: Largest pharma industry in India
 2015: Expands in more than 150
countries world wide.

5. In Pakistan 1948
In Karachi Landhi and Korangi
Permanent Employees Approx. 1460
Competitors GSK, Getz, Sanofi,
Wyeth, etc.

6. To be premier health care company in Pakistan.
To deliver consistently superior products and
services with contribute significantly to improve
the quality of life of the consumers. This will be
achieved while ensuring that the interests of all
stakeholders including healthcare providers,
employees, shareholders and communities are
secured. Abbott Pakistan will comply at all
times with applicable local laws and regulations
conform to highest standards of local
CGMP/EHS and ether to the Corporate Code
of Business conduct and Ethics.

7.  Abbott pharmaceutical products
 Abbott nutritional products
 Abbott diagnostics services
 Abbott diabetes care

8.  Pharmaceutical: Arinac, Klaricid,
Brufen, Citro-soda, Cremaffin, Mospel,
Daycor, Flexin etc…
 Nutrition: Ensure, Pediasure, Similac,
Glucerna etc.
 Diagnostics: CELL-DYN, Architect,
immunoassay chemistry tests etc.
Diabetes: Freestyle.

9.  Political Environment
- Changes in tax laws
- Pakistan india relationship
 Economical environment
- Interest rates
- Stock market
 Social analysis
- Number of births
- Number of doctors

10.  Technological environment
- Shift of R&D from USA to China
 Legal environment
- Pricing issues
 Environmental analysis
- Natural disaster

11. Key Internal Factors Weight Rating Weighted
Score
Strengths
Brand image 0.2 3 0.6
Product quality 0.15 4 0.6
Antibiotic producers 0.05 2 0.10
Diverse product line 0.18 3 0.54
Immunoassays 0.07 2 0.14
Weaknesses
Slow production 0.09 2 0.18
Few cardiac and anti-epliptic
medicines
0.12 3 0.36
Centralized decision making 0.06 1 0.06
Lack of advertisement 0.08 2 0.16
Total 1 2.74

12. Key Internal Factors Weight Rating Weighted
Score
Opportunities
Increasing population 0.2 2 0.4
Increasing different diseases 0.24 3 0.72
Increasing number of doctors 0.1 1 0.1
Water pollution 0.09 1 0.09
Threats
Tax laws 0.07 2 0.14
Political instability 0.3 1 0.3
High inflation rate 0.15 4 0.6
Competitors 0.05 1 0.05
Total 1 2.4

13. Critical Success Factors Weights Abbott Getz Pharma
Evo
Rate W.S Rat
e
W.S Rat
e
W.S
Brand Image 0.08 3 0.24 2 0.16 2 0.16
Technology 0.14 3 0.42 2 0.28 1 0.14
Quality 0.14 3 0.42 1 0.14 2 0.28
Strong Image 0.07 2 0.14 2 0.14 1 0.07
Price 0.06 3 0.18 2 0.12 2 0.12
Product Line 0.09 4 0.36 2 0.18 2 0.18
Productivity 0.09 3 0.27 1 0.09 2 0.18
Market Share 0.12 4 0.48 1 0.12 2 0.24
Customer Loyalty 0.15 3 0.45 2 0.30 1 0.15
Advertisement 0.06 2 0.12 1 0.06 1 0.06
Total 1 3.08 1.59 1.58

14. Strengths
- Brand image.
- Product quality.
- Antibiotic producers.
- Diverse product line.
- Market leader in immunoassays.
Weaknesses
- Development of new product is very
slow.
- Few cardiac medicines are available
in market.
- Centralized decision making.
- Lack of advertisement.
Opportunities
- Increasing population.
- Increasing different diseases.
- Increasing number of doctors.
- Increasing heart diseases.
Threats
- Tax laws
- Political instability
- High inflation rate
- Large pharmaceutical industry (i.e.
competitors)
SWOT

15.  S-O Strategies
- Antibiotics may help to overcome different diseases.
(S3, O2)
- Advantage of diverse product by subscription of more
medicines to patients. (S4,O3)
 W-O Strategies
- Increase new researchers in R&D. (W1,O1)
- Increase cardiac medicines. (W2, O4)
 S-T Strategies
- High inflation rates will have an impact on company’s
profit margin as company has a diverse
product line. (S4, T3)
 W-T Strategies
- Lack of advertisements will provide an opportunity to
the competitors to overcome the market. (W4,T4)

16. Star Question Mark
- Brufen - Similac Mom
- Surbex Z - Mospel
- Ensure
Cash Cow Dog
- Somogel - Dijex
- Burnol - Froben

17. Internal Strategic Position External Strategic Position
Financial
Strength
Competitive
Advantage
Environmental
Stability
Industry
Strength
Return on
investment
+3 Market
share
-3 Technology -2 Growth
potential
+3
Working
capital
+2 PLC -2 Rate of
inflation
-3 Profit
potential
+2
Cash flow +4 Customer
loyalty
-1 Competitive
pressure
-2 Productivity +5
Inventory
turnover
+2 Control over
suppliers &
distributors
-4 Risk
involved in
business
-3 Financial
stability
+4
Total 11 -10 -10 14
Average 2.75 -2.5 -2.5 3.5

18. Quadrant 11 Quadrant 1
Quadrant 111 Quadrant 1V
Weak
Competitive
position
Strong
Competitive
position
Rapid Market Growth
Slow Market Growth

19. The IFE total weighted scores
The EFE
total
weighted
scores
Strong
3.0 to 4.0
Average
2.0 to 2.99
Weak
1.0 to 1.99
High
3.0 to 4.0
Medium
2.0 to 2.99
Low
1.0 to 1.99
1 11 111
1V V V1
V11 V111 X1

20. Integration Intensive
Key factors Weights AS TAS AS TAS
Strengths
Brand image. 0.2 3 0.6 3 0.6
Product quality. 0.15 3 0.45 3 0.45
Diverse product line. 0.18 2 0.36 2 0.36
Market leader in immunoassays. 0.07 1 0.07 2 0.14
Antibiotic producers. 0.05 1 0.05 2 0.10
Weaknesses
Slow production. 0.09 2 0.18 3 0.18
Few cardiac medicines. 0.06 1 0.06 1 0.06
Centralized decision making. 0.08 2 0.16 3 0.24
Lack of advertisement. 0.12 1 0.12 4 0.48
Total 1

21. Integration Intensive
Key factors Weights AS TAS AS TAS
Opportunities
Increasing population. 0.2 2 0.4 3 0.6
Increasing different diseases. 0.09 1 0.09 2 0.18
Increasing number of doctors. 0.24 2 0.48 4 0.96
Increasing heart diseases. 0.1 3 0.3 4 0.4
Threats
Tax laws 0.07 - - - -
Political instability 0.15 1 0.15 2 0.30
High inflation rate 0.1 1 0.1 2 0.2
Competitors 0.05 3 0.15 4 0.20
Total 1 3.72 5.45

22. It can be concluded that
comparatively Abbott should focus on
the marketing of its product and also
increase its productivity. Positive
points include the brand image and
loyalty of the customers who trust their
products and use them in the
availability of the large number of
substitutes.

23.  Abbott should focus on the growth of new products
specially related to the medicines of the heart and
epileptic patients.
 In order to create awareness Abbott should focus
on the advertising strategy.
 As Abbott is widely spread globally so
decentralized decision making should be followed
so as to take the decisions quickly in order resolve
the issues as soon as possible.
 Market development strategy and as a contingency
plan horizontal strategy would help to create
innovations in the lacking area of the company.